ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

selinexor

Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.

Drug pageSelinexor: every studyMany companies study it; this page follows only the 40 they lead. All 163 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 13, 201540 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Karyopharm Therapeutics316 open or runningphase 3since Oct 13, 2015May 16, 2012Dec 2026phase 3 · NCT04442022
Antengeneits history only40 open or runningphase 2since Apr 30, 2019Apr 30, 2019none ahead
Oncotherapeuticsits history only22 open or runningphase 1since Aug 12, 2020Aug 12, 2020Apr 1, 2027phase 1 · NCT06225310
AbbVieits history only11 open or runningphase 3since Nov 28, 2023Nov 28, 2023Dec 2027phase 3 · NCT06158841
Qilu Pharmaceuticalits history only11 open or runningphase 3since Aug 13, 2025Aug 13, 2025Dec 2027phase 3 · NCT07138209
Sarah Cannon Research Instituteits history only11 open or runningphase 2since Mar 1, 2021Mar 1, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Karyopharm Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since May 16, 2012.

  1. Dec 2, 2015Phase 2 study in Multiple MyelomaNCT02628704 · United States
  2. Apr 7, 2017Phase 3 study in Multiple MyelomaNCT03110562 · 402 enrolled · United States, Australia, Austria and more
  3. May 18, 2018Phase 3 study in Endometrial NeoplasmsNCT03555422 · 263 enrolled · United States, Belgium, Canada and more
  4. Feb 3, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04256707 · 80 enrolled · Israel
  5. Apr 14, 20202 phase 2 studies in Coronavirus InfectionsNCT04349098, NCT04355676
  6. Jun 1, 20202 phase 2 studiesNCT04421378, NCT04414475
  7. Jun 10, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04442022 · 501 enrolled · United States, China, Israel and more
  8. Sep 9, 2020Phase 2 study in Primary MyelofibrosisNCT04562870 · 112 enrolled · United States, China, France and more
  9. Sep 14, 2020Phase 3 study in Primary MyelofibrosisNCT04562389 · 353 enrolled · United States, Australia, Belgium and more
  10. Feb 22, 2021Phase 2 study in MelanomaNCT04768881 · 15 enrolled · United States
  11. Apr 17, 2021Phase 2 study in Colorectal NeoplasmsNCT04854434 · 13 enrolled · United States
  12. Nov 3, 2022Phase 3 study in Endometrial NeoplasmsNCT05611931 · 257 enrolled · United States, Australia, Belgium and more
  13. Jul 24, 2023Phase 2 study in Primary MyelofibrosisNCT05980806 · 58 planned · United States, Belgium, Bulgaria and more
  14. Nov 19, 2026Phase 2 study terminatedStudy stoppedNCT02227251 · “Terminated in alignment with FDA agreement to withdraw accelerated approval of DLBCL indication. This withdrawal is not due to safety con…”

Ahead

  1. Dec 2026Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04442022
  2. Jun 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT05980806
  3. Jan 2028Primary completion: phase 2 study in Multiple MyelomaNCT04414475

TargetBeta

XPO1 →read by rule
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule

Other programs on XPO1

ProgramCompanyFurthest phaseStudies
TQB3107Sino Biopharmaceuticalphase 11

Studies

All 31 Karyopharm Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05980806Primary Myelofibrosis · United States, Belgium, Bulgaria and more2RecruitingJun 202758
NCT05611931Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingMay 22, 2026257
NCT04854434Colorectal Neoplasms · United States2TerminatedJun 24, 202213
NCT04768881Melanoma · United States2TerminatedSep 22, 202315
NCT04562389Primary Myelofibrosis · United States, Australia, Belgium and more3Active, not recruitingFeb 20, 2026353
NCT04562870Primary Myelofibrosis · United States, China, France and more2Active, not recruitingSep 2026112
NCT04442022Lymphoma, Large B-Cell, Diffuse · United States, China, Israel and more3Active, not recruitingDec 2026501
NCT04414475Multiple Myeloma · Greece, Israel2RecruitingJan 2028127
NCT04421378Glioblastoma · United States, Canada2TerminatedJul 3, 202374
NCT04355676Coronavirus Infections2WithdrawnAug 30, 20200
NCT04349098Coronavirus Infections · United States, Austria, France and more2CompletedOct 5, 2020190
NCT04256707Carcinoma, Non-Small-Cell Lung · Israel2CompletedJul 31, 202480
NCT03555422Endometrial Neoplasms · United States, Belgium, Canada and more3CompletedJan 22, 2022263
NCT03110562Multiple Myeloma · United States, Australia, Austria and more3CompletedFeb 18, 2020402
NCT02628704Multiple Myeloma · United States2WithdrawnJun 20170
NCT02606461Liposarcoma · United States, Belgium, Canada and more3CompletedOct 28, 2020342
NCT02431351Myelodysplastic Syndromes2WithdrawnDec 20170
NCT02389543Multiple Myeloma2WithdrawnJan 20180
NCT02367690Diabetic Foot · New Zealand2WithdrawnMay 20150
NCT02336815Multiple Myeloma · United States, Austria, Belgium and more2CompletedJul 26, 2019202
NCT02314247Lymphoma, T-Cell, Peripheral · Australia, Singapore2TerminatedJan 201616
NCT02227251Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more2TerminatedJun 2, 2026279
NCT02213133Carcinoma, Squamous Cell · United States, Canada2TerminatedDec 10, 201545
NCT02146833Prostatic Neoplasms · United States2TerminatedApr 1, 201620
NCT02138786Richter's Transformation · United States, Germany, Poland and more2TerminatedAug 31, 201627
NCT02088541Leukemia, Myeloid, Acute · United States, Canada, Denmark and more2CompletedJan 8, 2018317
NCT02025985Ovarian Neoplasms · Belgium, Denmark2CompletedJan 24, 2017116
NCT01986348Glioblastoma · United States, Denmark, Netherlands2TerminatedJan 23, 202076
NCT01896505Sarcoma · United States, Canada1CompletedOct 21, 201654
NCT01607905Carcinoma, Squamous Cell · United States, Canada, Denmark1CompletedMar 15, 2016192
NCT01607892Hematologic Neoplasms · United States, Canada, Denmark1CompletedOct 13, 2015286

How it is read

Names in the registry

  • “Selinexor”, 32 entries
  • “Selinexor (combination therapy)”, 3 entries
  • “Selinexor 40 mg”, 2 entries
  • “Selinexor 60 mg”, 2 entries
  • “ATG-010”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.